Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Nimer S AlkhatibNancy K SweitzerChristopher S LeeBrian ErstadMarion SlackMahdi GharaibehJason KarnesWalter KlimeckiKenneth RamosIvo AbrahamPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
This independent ex ante economic evaluation suggests that genetically targeted treatment with bucindolol is unlikely to yield clinicoeconomic benefits over empirical treatment with carvedilol in NYHA III/IV HF.